Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry A Jacobson

Showing results (131-140 of 182) with videos related to

Pageof 19
Sort By:
Journal of the American Heart Association|April 4, 2022
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-ITSenthil Selvaraj, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology|January 14, 2022
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-ITNickpreet Singh, Deepak L Bhatt, Michael Miller, et al.
Cardiovascular Drugs and Therapy|April 20, 2017
The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater ReliabilityRobert S Rosenson, Kate Miller, Martha Bayliss, et al.
European Heart Journal Open|November 30, 2023
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSynMichael Miller, Deepak L Bhatt, Eliot A Brinton, et al.
Journal of Clinical Lipidology|May 23, 2019
The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapyTerry A Jacobson, Mary Katherine Cheeley, Peter H Jones, et al.
Journal of Clinical Lipidology|March 25, 2023
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive CardiologySalim S Virani, Karen Aspry, Dave L Dixon, et al.
American Journal of Preventive Cardiology|March 27, 2023
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive CardiologySalim S Virani, Karen Aspry, Dave L Dixon, et al.
American Journal of Preventive Cardiology|April 20, 2026
Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-ITRahul Aggarwal, Deepak L Bhatt, Michael Miller, et al.
Journal of Clinical Lipidology|November 22, 2021
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing groupPeter W F Wilson, Terry A Jacobson, Seth S Martin, et al.
Journal of Clinical Lipidology|October 2, 2013
Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care settingRoss J Simpson, Kaan Tunceli, Dena R Ramey, et al.
Pageof 19

Showing results (131-140 of 182) with videos related to

Sort By:
Pageof 19
Journal of the American Heart Association|April 4, 2022
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-ITSenthil Selvaraj, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology|January 14, 2022
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-ITNickpreet Singh, Deepak L Bhatt, Michael Miller, et al.
Cardiovascular Drugs and Therapy|April 20, 2017
The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater ReliabilityRobert S Rosenson, Kate Miller, Martha Bayliss, et al.
European Heart Journal Open|November 30, 2023
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSynMichael Miller, Deepak L Bhatt, Eliot A Brinton, et al.
Journal of Clinical Lipidology|May 23, 2019
The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapyTerry A Jacobson, Mary Katherine Cheeley, Peter H Jones, et al.
Journal of Clinical Lipidology|March 25, 2023
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive CardiologySalim S Virani, Karen Aspry, Dave L Dixon, et al.
American Journal of Preventive Cardiology|March 27, 2023
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive CardiologySalim S Virani, Karen Aspry, Dave L Dixon, et al.
American Journal of Preventive Cardiology|April 20, 2026
Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-ITRahul Aggarwal, Deepak L Bhatt, Michael Miller, et al.
Journal of Clinical Lipidology|November 22, 2021
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing groupPeter W F Wilson, Terry A Jacobson, Seth S Martin, et al.
Journal of Clinical Lipidology|October 2, 2013
Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care settingRoss J Simpson, Kaan Tunceli, Dena R Ramey, et al.
Pageof 19